Home / Business and Economy / CVS Reaches Insulin Pricing Deal With FTC
CVS Reaches Insulin Pricing Deal With FTC
24 Mar
Summary
- CVS Health has agreed to a proposed settlement with the FTC.
- The agreement concerns insulin pricing practices by its Caremark unit.
- The settlement is expected to be finalized in the coming weeks.
CVS Health has reached a proposed settlement agreement with the Federal Trade Commission (FTC) concerning insulin pricing. This agreement addresses a decade of regulatory and legislative scrutiny faced by pharmacy benefit managers regarding their pricing strategies.
The company’s pharmacy benefit management division, Caremark, has reportedly maintained a focus on lowering prescription drug expenses. This proposed settlement is a significant step in resolving ongoing investigations into these practices.
CVS Health anticipates that the settlement process will be finalized in the upcoming weeks. The final terms of the agreement are still pending and will be officially confirmed once the settlement is formally concluded.
